anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During the routine dissection classes for undergraduate medical students, we encountered a rare anatomical variation concerning the aberrant origin and course of the accessory splenic artery. The splenic artery is one of the direct branches of the coeliac trunk. During its tortuous course, it supplies the pancreas with greater curvature of the stomach and spleen. The accessory splenic artery originating from the main trunk of splenic artery, too, follows the same tortuous course while running through the lesser sac and supplies the posterior part of the spleen via the splenophrenic ligament. The accessory splenic artery is gaining clinical importance during various GI surgeries and some radiological procedures. The unnoticed accessory splenic artery damage may result in tremendous bleeding while performing GI-based surgery or radiological investigation like angiography. In our case report, the accessory splenic artery is an aberrant origin from the initial part of the actual splenic artery. Knowledge regarding the origin, course and termination is of utmost importance to GI surgeons, radiologists, and anatomists.
Participants in this group will receive a total of 5 daily sessions of sham shockwave therapy within a week. Sham therapy will be applied to the penis and to the left and right crus (shaft near the base).
FIELD: medicine. SUBSTANCE: method involves preliminarily irradiating 5% glucose solution with X-ray radiation at a dose of 0.2-0.5 Gr/ml and introducing into a newborn organism immediately before and after giving antibacterial preparations. Infectious toxicosis symptoms are reduced at the first day after irradiated 5% glucose solution is transfused. The children start sucking themselves, augment in weight, become more active. Their general state normalizes 2-3 days earlier than that is the case in patients receiving ordinary care. Irradiated glucose transfusion exerts stimulating influence over anti-endotoxin immunity in cases of pyoseptic diseases. The influence manifests itself in increased endotoxin binding reserve due to granulocytes and growing titers of anti-endotoxin antibodies at the third day after infusion. In applying complex therapy including irradiated glucose transfusion, marked correction of homeostasis and acid-base blood state disorders takes place in cases of severe bacterial infection. EFFECT: enhanced effectiveness of treatment; lower lethal outcomes level; avoided application of blood preparations.
###  General

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. There are case reports of patients succumbing to fatal dysrhythmias late after overdose; these patients had clinical evidence of significant poisoning prior to death and most received inadequate gastrointestinal decontamination. Monitoring of plasma drug levels should not guide management of the patient.

###  Gastrointestinal Decontamination

All patients suspected of tricyclic antidepressant overdose should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage. EMESIS IS CONTRAINDICATED.

###  Cardiovascular

A maximal limb-lead QRS duration of ≥ 0.10 seconds may be the best indication of the severity of the overdose. Intravenous sodium bicarbonate should be used to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate, hyperventilation may also be used. Concomitant use of hyperventilation and sodium bicarbonate should be done with extreme caution, with frequent pH monitoring. A pH > 7.60 or a pCO2 < 20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide). In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis generally have been reported as ineffective in tricyclic antidepressant poisoning.

###  CNS

In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines, or if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in consultation with a poison control center.

###  Psychiatric Follow-up

Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery phase. Psychiatric referral may be appropriate.

###  Pediatric Management

The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.
Gingivitis group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The entire non-surgical periodontal treatment of gingivitis groups was completed in a total of 2 sessions in a week.
Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
Transient global amnesia (TGA) is a perplexing neurological condition primarily affecting older adults, characterised by the acute onset of anterograde amnesia. Patients remain oriented to self and symptoms resolve within 24 hours. Before diagnosing TGA, conditions such as transient ischaemic attack and stroke must be excluded. We present a case of a woman in her 60's who experienced acute onset memory impairment and confusion after taking rizatriptan for migraine and temazepam for insomnia the previous night. Initially treated as an acute ischaemic stroke with tissue plasminogen activator, a thorough neurological examination eventually led to a diagnosis of TGA after other potential causes were ruled out. This case suggests that the combined use of triptans and benzodiazepines may predispose patients to TGA. It also highlights the importance of differentiating TGA from other cerebrovascular diseases in order to reduce patients' exposure to the thrombolytic agent and the cost of hospitalisation.
Students in the Jigsaw technique group are divided into 5 home groups consisting of 8 people.Each student in the groups was randomly included to be an expert on a subject under 8 headings.In the home group, students assigned to different subject specializations were combined with students selected as experts in the same subject. This group was called the "expert group".The experts came together a week later, explained what they had learned on the common topic, discussed the topics they had taken notes while researching and reading in expert groups, and noted any additional points or missing parts they had learned. After completing their tasks in the expert groups, students returned to their home groups. They explained the information they learned in the expert group to each other in the home group, and as a home group, they brought together different topics and reported the main topic.
Participants who received double-blind ataluren during Study 009 will continue to receive open-label ataluren 3 times per day TID: 10 milligram (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
PURPOSE:To provide the titled agent containing proline or its salt as an active component, and capable of preventing cancer caused by N-nitroso compounds by preferentially detoxicating the carcinogenic N-nitroso compound in the stomach. CONSTITUTION:An agent for preventing the cancer caused by N-nitroso compounds, e.g. hepatic cancer, gastric cancer, etc., is prepared by using proline or its salt as an active component. Proline is preferably natural L-proline, DL- proline, their Na salt, K salt, etc. When proline is brought into contact with an aliphatic amine in the stomach, it reacts preferentially with nitrite ion to form non-toxic N-nitrosoproline and effectively inhibits the formation of a carcinogenic N-nitroso compound in the body. The agent can be prepared in a form to be taken spontaneously, preferably as an additive of foods (e.g. soy, sauce, mayonnaise, etc.).
The mothers were asked to sing lullabies, and their voices were recorded in a quiet environment. Which lullaby they would sing was left to the mothers' discretion, and the audio recording process took an average of 2-3 minutes. The voice recordings taken were applied for a total of 15 minutes before, during and after the nasal CPAP application.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
The subject matter of the invention relates to a solid oral composition of isosorbide-5-mononitrate in the form of a controlled release tablet which can be divided into several parts. The tablet is marked by the presence of scoring in a direction perpendicular to its length and height of a depth more than 1/2 and approximately 2/3 of its height. The broken surface is thus reduced so that the maximum increase in the area of the tablet resulting from breakage into at least three pieces is always less than 15%. This ensures uniform release of the active ingredient of the fragmented pharmaceutical form in comparison with the intact tablet. The tablet is also marked by the high physical stability of the active ingredient. <IMAGE>
FIELD: molecular biology, biochemistry. SUBSTANCE: invention relate to novel class of nucleic acids ligands with high affinity degree that bind with essential molecule-target specifically. Method involves interaction of a mixture of single-stranded nucleic acids with target, separation of nucleic acids exhibiting enhanced affinity to this target from mixture remained. After separation of nucleic acids exhibiting enhanced affinity to this target amplification is carried out to obtain ligand-enriched mixture of nucleic acids and interaction of single-stranded nucleic acids with target is provided. Nucleic acids exhibiting enhanced affinity to this target are separated and their amplification is carried out to obtain ligand- enriched mixture of nucleic acids. The above enumerated stages are repeated using ligand-enriched mixture of nucleic acids after each following repeat as many times as necessary to obtain the enrichment level that is sufficient for preparing ligand solution to indicated target. Nucleic acid molecules that effect on function of molecule-target are identified by the above-mentioned method and tested for enhanced affinity to target to be interested and for their capacity to effect on functions of indicated molecule-targets. Mixture of nucleic acids comprising conservative segment and randomized segment is prepared. Interaction of mixture of nucleic acids with target is carried out under conditions favorable for binding with formation of pairs "nucleic acid target" and unbound nucleic acids. Unbound nucleic acids are separated from pair "nucleic acid target" and amplification of separated nucleic acid pairs "nucleic acid target" is carried out to obtain ligand-enriched mixture of nucleic acids. Mixture of nucleic acids comprises at least 10 9  of single- stranded nucleic acids. Nucleic acids comprise conservative nucleotide fragment and randomized nucleotide fragment. Randomized segment comprises chain of 8-100 following one after another nucleotides. Nucleic acid ligand no occurring in nature is identified by method given above. Ligand is not nucleic acid exhibiting the known physiological binding function by molecule-target and shows affinity for specific binding with molecule- target. Such molecule-target has tree-dimensional structure distinguishing from polynucleotide structure binding with indicated nucleic acid ligand by mechanism depending on base pairing by Watson-Crick model or by triple helix binding. Base sequences of nucleic acids and ribonucleic acids are given in the invention claim and in description. Invention allows to prepare the novel class of nucleic acids compounds, i. e. so called nucleic acid antibodies that exhibit affinity for specific binding with three-dimensional molecule-targets. EFFECT: improved methods of identification, preparing and selection of nucleic acids. 83 cl, 35 dwg, 13 tbl, 13 ex
All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation. The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
BACKGROUND: Recent studies have revealed that sarcopenia is associated with postoperative complications and poor prognosis. Although neoadjuvant chemotherapy is a promising treatment for gastric cancer, its toxicity may lead to the loss of skeletal muscle mass. This study investigates the changes in skeletal muscle mass during neoadjuvant chemotherapy and its clinical impact on patients with locally advanced gastric cancer.
METHODS: Fifty patients who completed two courses of neoadjuvant chemotherapy followed by surgery were included. Skeletal muscle mass was measured using computed tomography images before and after chemotherapy. The proportion of skeletal muscle mass change (%SMC) during neoadjuvant chemotherapy and its cutoff value was explored using the receiver operating characteristic for the overall survival of patients undergoing R0 resection. Risk factors of skeletal muscle mass loss were also evaluated.
RESULTS: Overall, 64% of patients had skeletal muscle mass loss during neoadjuvant chemotherapy (median %SMC -3.4%; range: -18.9% to 10.3%). Multivariable analysis identified older age (≥70 years) as an independent predictor of skeletal muscle mass loss (mean [95% confidence interval]: -4.70% [-8.83 to -0.58], p = 0.026). Among 43 patients undergoing R0 resection, %SMC <-6.9% was an independent poor prognostic factor for overall survival (hazard ratio, 11.53; 95% confidence interval, 2.78-47.80) and relapse-free survival (hazard ratio 4.54, 95% confidence interval 1.50-13.81).
CONCLUSIONS: Skeletal muscle mass loss occurs frequently during neoadjuvant chemotherapy for locally advanced gastric cancer and could adversely affect survival outcomes.
The invention relates to a method for preparing control-release paste medium, comprising cyclodextrin, drug, macromolecule and elasticizer. The invention uses package and macromolecule mixing technique to prepare the control-release paste medium with needed rigidity and rheological property. The invention is characterized in that it uses insoluble cellulose ethyl ether and low-permeability acrylic resin mixture medium as the skeleton control-release material, and uses cyclodextrin and ealsticizer to adjust the rheological property and drug release speed of the paste, uses glycerin and drug grind method to pack the drug. Via external release degree test, the paste which contains Minocycline Hydrochloride, polycyclic acid or the like, via slurry method (at 37Deg. C, 100rpm) can reach 20-40% in 1h, 40-60% in 3h, 50-80% in 7h, and 80-90% in 12h. The inventive paste can be used to treat mouth and vaginal diseases.
This is an in vivo study designed to acquire human gastrointestinal (GI) physiology data from healthy subjects which are necessary for mechanistic absorption model development. Each subject will be asked to complete two phases. The first phase will include collection of fluids from stomach and gastrointestinal (GI) tract through intubation (putting a GI tube from mouth into stomach and intestines), blood, urine and feces, and measure glipizide concentrations.

The second phase will not involve the intubation procedure. Blood, urine and feces will be collected for measurement of glipizide concentrations. A minimum of 5 days will separate each of the two study phases. The objectives of this study are, as follows: Objective #1: To characterize the plasma, gastrointestinal fluid, urine, and feces concentrations of glipizide after oral administration of modified release formulations; Objective #2: To compare the pharmacokinetics of glipizide between the two modified release formulations; Objective #3: To compare the pharmacokinetics of glipizide with and without gastrointestinal intubation; Objective #4: To collect gastrointestinal physiology data in volunteers receiving an oral MR formulation of glipizide. These in vivo results will be used to validate in vitro dissolution methods and to support computational and mathematical modeling efforts, in order to develop an oral drug product optimization process that may be applied to future drugs to maximize oral drug safety and efficacy.
FIELD: medicine, immunology. SUBSTANCE: method involves saline extraction of human serum blood alcoholic extract, removal of lipoproteids using chloroform, isolation of end product by alcohol precipitation by centrifugation, dilution of immunoglobulin precipitate in glycine solution, sterilizing filtration and lyophilization. Human plasma blood alcoholic precipitate is diluted using sodium chloride solution with ionic strength 0.01-0.015, 10-20 volumes with respect to precipitate weight. Immunoglobulin precipitate is isolated by addition of ethyl alcohol, precipitate is centrifuged and diluted by 10-15 times using 0.05-0.07 M buffer solution, pH 3.8-3.9, and sodium chloride is added to obtained solution up to final concentration 0.075-0.1 M and chloroform to concentration 13-15%. Obtained lipoproteids precipitate is separated by centrifugation carrying out this procedure two times, not less. To the prepared supernatant sodium hydroxide and ethyl alcohol are added, mixture is centrifuged and filtered. Precipitate of the end product is diluted in glycine solution and pH of solution is brought about to 4.0-4.5. Invention provides enhancement of quality of the end product due to increase of content of immunoglobulins A and M in preparation obtained. Invention can be used for immunotherapy and immunoprophylaxis of bacterial and viral preparations. EFFECT: improved method of preparing. 2 ex
RESEARCH QUESTION: The aim of the study is to assess the status quo of emotional competence in people with chronic pain. How do patients experience themselves regarding to their ability to perceive, express, and regulate emotions? And does this assessment coincide with the assessment of emotional competence (EC) by mental health professionals?
METHODS: The study took place in the context of interdisciplinary multimodal pain therapy at an outpatient clinic in N = 184 adult German-speaking individuals with non-cancer-related chronic pain. EC was assessed at the end of therapy using the self- and third-party assessment scales of the Emotional Competence Questionnaire. The external assessment was performed by the mental health team. Standard scores were created using the norm sample provided by questionnaires. These were analyzed descriptively and inferentially.
RESULTS: Self-perceived EC was average (Mself_total = 99.31; SD = 7.78). The mental health professionals predominantly rated the emotional competence of the patients significantly lower (Mexternal_total = 94,70; SD = 7,81; F(1.179) = 35,73; p < 0.001; η2 = 0.17). Emotional expressivity, as a component of EC, was externally rated as below average (Mexpressivity_external = 89.14, SD = 10.33).
DISCUSSION: Patients with chronic pain rate themselves as unimpaired in terms of their daily emotional awareness, expression, and regulation abilities. At the same time, mental health professionals rate these same individuals as significantly less emotionally competent. The question remains open as to what extent the divergent assessments can be explained by assessment bias.
Protein kinases (PKs) are proteins at the core of cellular signalling and are thereby responsible for most cellular physiological processes and their regulations. As for all intracellular proteins, PKs are subjected to Brownian thermal energy that tends to homogenise their distribution throughout the volume of the cell. To access their substrates and perform their critical functions, PK localisation is therefore tightly regulated in space and time, relying upon a range of clustering mechanisms. These include post-translational modifications, protein-protein and protein-lipid interactions, as well as liquid-liquid phase separation, allowing spatial restriction and ultimately regulating access to their substrates. In this review, we will focus on key mechanisms mediating PK nanoclustering in physiological and pathophysiological processes. We propose that PK nanoclusters act as a cellular quantal unit of signalling output capable of integration and regulation in space and time. We will specifically outline the various super-resolution microscopy approaches currently used to elucidate the composition and mechanisms driving PK nanoscale clustering and explore the pathological consequences of altered kinase clustering in the context of neurodegenerative disorders, inflammation, and cancer.
The treatment decisions are based on relying on radiological parameters such as using the RECIST criteria and measuring the rise in certain serum tumour biomarkers. However, the disadvantage of this is that this method can take many months to detect a change in disease volume. An improved understanding of genetics and cancer and potential gene sequencing can help achieve personalised treatment for patients. However, there are many questions and issues that still need to be answered and require urgent attention before being able to achieve optimate patient stratification. We need to identify better tumour biomarkers to detect disease progression, show real time response to treatment and understand why tumours evolve to becoming more aggressive. This study hopes to address these issues by proposing a multicentre prospective study to investigate the presence and role of ctDNA in advanced thyroid cancer including differentiated thyroid cancer , medullary thyroid cancer and Anaplastic Thyroid Cancer.